The Drug Discovery Process: How Do New Glaucoma Medications Come to Market?
In the United States of America, no drugs have been approved to treat glaucoma in the past 25 years. The vast majority of drugs in the glaucoma specialist’s armamentarium are indicated for the reduction (or treatment) of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension - or words to that effect. Internationally, the situation is quite different, but this review will focus primarily on how drugs (and more specifically, glaucoma drugs) are discovered and developed for the US market.
KeywordsActive Pharmaceutical Ingredient Isopropyl Ester Work Breakdown Structure European Public Assessment Report Brimonidine Tartrate
- 2.Becker B. Diamox and the therapy of glaucoma. Am J Ophthalmol. 1954;38:16–17.Google Scholar
- 3.Ponticello GS, Sugrue MF, Plazonnet B, et al. Dorzolamide, a 40-year wait: from an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. In: Borchardt RT, Freidinger RM, Sawyer TK, Smith PL, eds. Integration of Pharmaceutical Discovery and Development. New York, NY: Plenum; 1998:555–574.Google Scholar
- 11.Hellberg MR, McLaughlin MA, Sharif NA, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S13-S33.CrossRefPubMedGoogle Scholar
- 15.Spilker B. Multinational Pharmaceutical Companies: Principles and Practices. 2nd ed. New York, NY: Raven; 1994.Google Scholar
- 16.Ng R. Drugs from Discovery to Approval. Hoboken, NJ: John; 2004.Google Scholar
- 17.Campbell JJ. Understanding Pharma - A Primer on How Pharmaceutical Companies Really Work. Raleigh, NC: Pharmaceutical Institute; 2005.Google Scholar